Literature DB >> 33591649

[The organizational aspects of security support of participants of clinical testing of vaccine "Gam-COVID-Vac"].

N B Naygovzina1, R U Khabriev2, A E Krasheninnikov3, A V Matveev4,5.   

Abstract

The COVID-19 pandemic resulted in many aftermaths, economic crisis and extra charging of health care. The development of vaccine against SARS-nCoV-2 agent turned out as the priority task of world and Russian medicine and pharmaceutics. The investigation of efficiency and safety of vaccines can be prolonged for many years that can aggravate the observed crisis. Having regard to the global scope and speed of pandemic spreading, the vaccine "Gam-COVID-Vac" was registered with special procedure by the Decree of the Government of the Russian Federation No. 441 of 03.04.2020 for accelerated access to civic turn-over. To monitor safety of vaccine on the basis of international experience, the decision was made to organize the independent Committee of monitoring data concerning efficacy and safety of vaccines applied to prevent COVID-19. The article presents rationale for necessity to create independent committee and to implement such a practice.

Entities:  

Keywords:  COVID; Pharmakonadzor; clinical trial; independent committee; monitoring; safety; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33591649     DOI: 10.32687/0869-866X-2021-29-1-5-13

Source DB:  PubMed          Journal:  Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med        ISSN: 0869-866X


  4 in total

Review 1.  Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.

Authors:  Zhan Zhang; Qi Shen; Haocai Chang
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

Review 2.  Advances in the design and development of SARS-CoV-2 vaccines.

Authors:  Xue-Liang Peng; Ji-Si-Yu Cheng; Hai-Lun Gong; Meng-Di Yuan; Xiao-Hong Zhao; Zibiao Li; Dai-Xu Wei
Journal:  Mil Med Res       Date:  2021-12-16

Review 3.  A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.

Authors:  Surojit Banerjee; Debadri Banerjee; Anupama Singh; Vikas Anand Saharan
Journal:  AAPS PharmSciTech       Date:  2022-03-21       Impact factor: 4.026

Review 4.  Viral vector and nucleic acid vaccines against COVID-19: A narrative review.

Authors:  Saeed Khoshnood; Roya Ghanavati; Maryam Shirani; Hossein Ghahramanpour; Mohammad Sholeh; Aref Shariati; Nourkhoda Sadeghifard; Mohsen Heidary
Journal:  Front Microbiol       Date:  2022-08-31       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.